Boulder, Colo., Sept. 26, 2016 – Accera, Inc., a clinical-stage biotechnology company focused on product development for Alzheimer’s disease, today announced that the company will present at the following upcoming investor conferences:
- 16th Annual Biotech in Europe Forum: Dr. Charles Stacey, president and CEO, will present an overview of the company on Tuesday, September 27, at 4 p.m. CEST at the Congress Center in Basel, Switzerland. Dr. Stacey will also participate in an Alzheimer’s disease panel at 2 p.m. CEST on the same day. The panel includes representatives from Novartis Institutes for BioMedical Research, Eli Lilly and Company, SV Life Sciences, Alzheimer’s Research UK and Heptares Therapeutics.
- Neuro Advance Boston: Dr. Stacey will moderate a panel discussion, “Novel Approaches to Alzheimer’s Disease,” on Wednesday, October 5, at 9:30 a.m. EDT at the Harvard Medical School’s Joseph B. Martin Conference Center in Boston. The panel includes representatives from EIP Pharma, vTv Therapeutics, AZTherapies, M3 Biotechnology, and Neurocentria.
Accera, Inc. is a clinical-stage biotechnology company based in Boulder, Colo., that is developing therapies for central nervous system disorders. The company’s proprietary scientific platform addresses unmet medical needs in brain health, including Alzheimer’s disease. Accera is focused on the clinical development of drugs with innovative mechanisms of actions. The company’s management team includes globally recognized specialists in central nervous system diseases and drug development, who together leverage the latest scientific knowledge and understanding of neurological disorders. Accera’s lead product candidate is AC-1204, a ketosis-inducing compound in a Phase 3 clinical study in patients with mild to moderate Alzheimer’s disease. For more information, visit www.accerapharma.com.
Follow Accera on Twitter at twitter.com/accerainc.
Accera Media Contacts:
Russo Partners LLC
Todd Davenport, Ph.D.
(858) 717-2310 Mobile
SOURCE Accera, Inc.